Considering a switch from IVIg to SCIg for primary immunodeficiency? Explore differences in responsibility, side effects, costs, and how each impacts quality of life.

“The approval of GAMMAGARD LIQUID ERC reinforces our commitment to supporting individualized treatment approaches for people with primary immunodeficiency, including a therapeutic option that has the ...

Evolve Biologics Inc. (“Evolve”), an innovative plasma-derived therapeutics company, today announced that it has successfully completed its adult and pediatric Phase III clinical trial of PlasmaCap IG ...

The intersection of cancer immunology and immunoglobulin expression has emerged as a dynamic field, challenging traditional views on immune responses and tumour biology. Research has demonstrated that ...

RESEARCH TRIANGLE PARK – Grifols, a global leader in plasma medicines, on Monday announced it has received approval from the U.S. Food and Drug Administration (FDA) for its new immunoglobulin (Ig) ...

Medically reviewed by Matthew Wosnitzer, MD Key Takeaways The rate of progression of immunoglobulin A nephropathy (IgAN) can ...

Immunoglobulin A (IgA) deficiency is the most common primary immunodeficiency in humans. It can increase the risk of allergies, asthma, and autoimmune disease. Primary immunodeficiencies are ...

Antibody. Illustration of an immunoglobulin antibody molecule. This Y-shaped molecule has two arms that can bind to specific antigens, for instance viral or bacterial proteins. In doing this it marks ...

GAMMAGARD LIQUID ERC [immune globulin infusion (human)] with Less Than or Equal to 2 µg/mL IgA in a 10% Solution is Approved for Intravenous or Subcutaneous Use in People Aged Two and Older with ...